<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Focal atrial tachycardia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Focal atrial tachycardia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Focal atrial tachycardia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter Kistler, MBBS, FRACP, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Samuel Lévy, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Atrial tachycardia (AT) is a regular atrial rhythm at a constant rate of &gt;100 beats per minute originating outside of the sinus node  (<a class="graphic graphic_waveform graphicRef74611" href="/d/graphic/74611.html" rel="external">waveform 1</a>) [<a href="#rid1">1</a>]. Focal ATs (also referred to as atrial ectopic tachycardias) arise from a single site within the left or right atrium, in contrast to macroreentrant atrial arrhythmias (eg, atrial flutter) and atrial fibrillation, which involve multiple sites or larger circuits.</p><p>In the past, focal ATs were considered to be due predominantly to enhanced automaticity. Thus, they were often referred to as automatic ATs. However, the more inclusive term focal AT is preferred, as this encompasses automatic, triggered, and microreentrant etiologies that cannot be distinguished easily on the surface electrocardiogram.</p><p>Focal ATs are usually paroxysmal and self-limited, although in some patients, focal AT may be present nearly continuously (ie, incessant AT). Incessant AT is important as it may be associated with left ventricular dysfunction [<a href="#rid2">2</a>]. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy", section on 'Atrial tachycardia'</a>.)</p><p>The characteristics and management of the common, repetitive forms of focal AT are discussed here. Macroreentrant atrial arrhythmias (eg, atrial flutter), atrial fibrillation, and other forms of supraventricular tachycardia are discussed in detail separately. (See  <a class="medical medical_review" href="/d/html/1048.html" rel="external">"Overview of atrial flutter"</a> and  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a> and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">BACKGROUND</span></p><p class="headingAnchor" id="H3"><span class="h2">Definition</span><span class="headingEndMark"> — </span>In 2001, the Joint Expert Group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology (now called the Heart Rhythm Society) classified regular ATs according to electrophysiologic mechanisms and anatomy [<a href="#rid1">1</a>]. The Joint Expert Group defined focal AT as "being characterized by atrial activation starting rhythmically at a small area (focus) from where it spreads centrifugally." This definition indicates that the arrhythmia arises from an area that is smaller than would be required for classical macroreentry, which conventionally is considered to be a circuit greater than 2 cm in diameter.</p><p class="headingAnchor" id="H4"><span class="h2">Incidence</span><span class="headingEndMark"> — </span>Focal AT is relatively uncommon, accounting for between 5 and 15 percent of arrhythmias in adults undergoing study for paroxysmal supraventricular tachycardia [<a href="#rid3">3</a>]. Males and females seem to be equally affected.</p><p class="headingAnchor" id="H5"><span class="h1">MECHANISMS AND ETIOLOGY</span></p><p class="headingAnchor" id="H6"><span class="h2">Electrophysiologic mechanisms</span><span class="headingEndMark"> — </span>The focal activity responsible for AT can be produced by three distinct electrophysiologic mechanisms [<a href="#rid3">3-6</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Enhanced automaticity</strong> – Enhanced automaticity refers to an acceleration of a normal automatic pacemaker by an increase in the slope of phase four depolarization  (<a class="graphic graphic_figure graphicRef64133" href="/d/graphic/64133.html" rel="external">figure 1</a>), shortening of the refractory period, a decrease in the threshold for excitation, or some combination of these mechanisms. (See  <a class="medical medical_review" href="/d/html/952.html" rel="external">"Enhanced cardiac automaticity"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Triggered activity</strong> – Triggered activity is the result of electrophysiologic phenomena called afterdepolarizations. Afterdepolarizations are focal electrical events that result in repeat depolarization of a single cell or small area prior to full repolarization. Early afterdepolarizations occur during the plateau phase of the action potential, while delayed afterdepolarizations occur during phase four.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Microreentry</strong> – Microreentry requires a small circuit, defined as &lt;2 cm to distinguish from macroreentry, in which conduction is sufficiently slow that the tissue can recover its excitability and be re-excited by the time the wave of depolarization returns. Such slow conduction classically occurs at discrete regions of fibrosis such as following ablation or surgery or anatomic sites of change in fiber orientation.</p><p></p><p>The hypothesis that cellular uncoupling is required for the development of focal atrial tachycardias is supported by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Low-amplitude fractionated electrograms are commonly found in the focal areas in which these atrial arrhythmias arise [<a href="#rid7">7,8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Focal arrhythmogenesis often occurs in regions of discontinuity in atrial architecture [<a href="#rid8">8</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Sites of origin</span><span class="headingEndMark"> — </span>Focal ATs do not occur randomly throughout the atria, but rather cluster at predefined anatomic locations [<a href="#rid9">9</a>]. These locations are characterized by alterations in myocardial fiber orientation or sites of automatic tissue. In a series of 186 patients with clinically documented paroxysmal or incessant AT, 63 percent of ATs arose in the right atrium (RA) and 37 percent in the left atrium (LA)  (<a class="graphic graphic_figure graphicRef62431" href="/d/graphic/62431.html" rel="external">figure 2</a>) [<a href="#rid10">10</a>]. The distribution of sites of origin among the right atrial tachycardias was:</p><p class="bulletIndent1"><span class="glyph">●</span>Tricuspid annulus (35 percent)  (<a class="graphic graphic_waveform graphicRef74611" href="/d/graphic/74611.html" rel="external">waveform 1</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Crista terminalis (34 percent)  (<a class="graphic graphic_waveform graphicRef50523" href="/d/graphic/50523.html" rel="external">waveform 2</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Coronary sinus ostium (17 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>Perinodal tissues (9 percent)</p><p class="bulletIndent1"><span class="glyph">●</span>RA appendage (4 percent)</p><p></p><p>Left atrial tachycardias were predominantly located around the pulmonary veins (67 percent)  (<a class="graphic graphic_waveform graphicRef57390" href="/d/graphic/57390.html" rel="external">waveform 3</a>). Less common sites of origin include the mitral annulus (17 percent), coronary sinus body (6 percent), left intraatrial septum (6 percent), and the LA appendage (4 percent) [<a href="#rid10">10,11</a>]. The non-coronary cusp is an unusual site for atrial tachycardia, which should be considered for apparent paraseptal tachycardias [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Associated conditions</span><span class="headingEndMark"> — </span>Focal AT may occur in patients with organic heart disease in response to atrial stretch due to elevated atrial pressure in conditions such as hypertension and cardiomyopathy. In addition to chronic heart disease, AT can also be associated with acute events such as a myocardial infarction, pulmonary decompensation, infection, excessive alcohol ingestion, hypokalemia, hypoxia, stimulants, cocaine ingestion, and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> [<a href="#rid13">13</a>]. More commonly AT occurs in the absence of heart disease and generally has a benign prognosis [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H17173656"><span class="h3">Incessant AT resulting in cardiomyopathy</span><span class="headingEndMark"> — </span>The term "incessant" is applied to an AT when the AT is present for at least 90 percent of the time a patient is monitored [<a href="#rid15">15</a>]. Incessant AT is often found in otherwise normal young individuals, including children, although it may occur in patients with organic heart disease [<a href="#rid16">16-19</a>]. The rate tends to be faster during the day than at night, and the rate may increase with exercise or pregnancy [<a href="#rid20">20</a>].</p><p>Incessant focal AT may be responsible for tachycardia-mediated cardiomyopathy, which refers to left ventricular (LV) chamber dilatation and systolic dysfunction in a patient with persistent tachyarrhythmias [<a href="#rid18">18,21,22</a>]. Focal ATs originating in the atrial appendages and pulmonary veins are more frequently associated with cardiomyopathy [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p class="headingAnchor" id="H1542581"><span class="h3">Post-atrial fibrillation ablation</span><span class="headingEndMark"> — </span>The incidence of atrial tachycardia appears to be higher among patients who have undergone catheter ablation for atrial fibrillation (AF) [<a href="#rid24">24</a>]. Catheter ablation of persistent AF may involve an extensive biatrial ablation strategy that combines linear ablation and the targeting of complex fractionated activity beyond pulmonary vein isolation. In a multicenter international randomized study, catheter ablation for persistent AF that involved targeting complex fractionated activity or linear ablation was not associated with an increase in freedom from AF compared with pulmonary vein isolation alone [<a href="#rid25">25</a>]. This study may translate to a more conservative approach to atrial substrate modification with a consequent reduction in post ablation atrial tachycardia. ATs post-AF ablation are often incessant, associated with rapid ventricular rates, and respond poorly to pharmacologic measures. Although they may be seen as a positive sign in the longer-term restoration of sinus rhythm, post-AF ablation AT poses specific challenges often requiring repeat catheter ablation procedures. (See  <a class="medical medical_review" href="/d/html/949.html" rel="external">"Atrial fibrillation: Catheter ablation", section on 'Efficacy'</a>.)</p><p class="headingAnchor" id="H303125331"><span class="h3">Medications</span><span class="headingEndMark"> — </span>A 2020 scientific statement from the American Heart Association details drugs associated with AT [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H21082008"><span class="h4">Digitalis toxicity</span><span class="headingEndMark"> — </span>In patients taking digitalis, toxicity should be suspected if a new AT develops, particularly if 2:1 or higher grade atrioventricular block is present. Digitalis should be discontinued in this case, and anti-digitalis antibodies should be considered if hemodynamic compromise is present or other dangerous arrhythmias accompany the tachycardia. (See  <a class="medical medical_review" href="/d/html/319.html" rel="external">"Digitalis (cardiac glycoside) poisoning"</a>.)</p><p class="headingAnchor" id="H20806678"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>Most patients with focal AT report palpitations. Palpitations can manifest in different ways. The abrupt onset of a rapid fluttering sensation in the chest or neck is most consistent with a tachyarrhythmia such as focal AT. The symptom burden is typically higher in focal compared with reentrant supraventricular tachycardia. (See  <a class="medical medical_review" href="/d/html/6835.html" rel="external">"Evaluation of palpitations in adults"</a>.)</p><p>Patients with focal AT can rarely present with syncope, predominantly if the ventricular heart rate exceeds 200 beats/minute. Syncope, however, is more frequently seen with a ventricular tachyarrhythmia such as ventricular tachycardia than with focal AT. (See  <a class="medical medical_review" href="/d/html/1049.html" rel="external">"Syncope in adults: Epidemiology, pathogenesis, and etiologies", section on 'Cardiac arrhythmias'</a>.)</p><p>Patients with other underlying cardiac comorbidities (eg, heart failure, angina) can present with symptoms associated with worsening of their underlying disease (eg, dyspnea, chest pain).</p><p class="headingAnchor" id="H15492827"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of focal AT is based primarily on electrocardiographic (ECG) findings demonstrating an atrial arrhythmia of &gt;100 beats per minute originating from outside the sinus node [<a href="#rid6">6</a>]. The tachycardia is generally sudden in onset and offset and frequently demonstrates a change in P-wave morphology. Focal AT is suggested by bursts of atrial activity with an isoelectric interval between P waves with confirmation of “focal” as opposed to macroreentry dependent on the findings at EP study. (See <a class="local">'Electrophysiologic study and catheter ablation'</a> below.)</p><p class="headingAnchor" id="H9"><span class="h2">Electrocardiographic features</span></p><p class="headingAnchor" id="H10"><span class="h3">P waves</span><span class="headingEndMark"> — </span>The atrial rate during focal AT is generally between 110 and 250 beats per minute. Infants, children and young adults often have faster rates.</p><p>The P-wave morphology can appear normal or abnormal, depending upon the site of origin of the tachycardia. If the focus is from the superior portion of the crista terminalis, the P wave may be similar in appearance to the sinus P wave. Usually, there is a subtle difference in P waves from sinus rhythm to AT, so comparison with an ECG with known sinus P waves is recommended whenever possible. ECG leads V1 and lead II are the most useful in assessing P-wave morphology.</p><p>Observation over several minutes with multiple ECGs is invaluable in distinguishing focal AT from sinus tachycardia. Although focal ATs are regular, the rate may accelerate or "warm up" in the first few beats of the tachycardia and decelerate in the last few beats. An abrupt onset or termination (eg, over three to four beats) favors a focal AT. Sinus tachycardia requires 30 seconds to several minutes to speed up or slow down.</p><p>In occasional patients, no P waves appear on the surface ECG, which may suggest atrioventricular nodal reentrant tachycardia (AVNRT) [<a href="#rid27">27</a>] as the responsible mechanism. However, this may occur with focal AT if the atrial and ventricular complexes are closely associated such that the P wave is buried in the QRS complex.</p><p class="headingAnchor" id="H11"><span class="h3">Atrioventricular relationship</span><span class="headingEndMark"> — </span>In focal AT, AV conduction is usually 1:1. The PR interval is often in the normal range, producing a long R-P interval, which can help to distinguish focal AT from other forms of supraventricular tachycardia (SVT). AT is unlikely if a P wave is present at tachycardia termination. (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'RP relationship'</a>.)</p><p>Mobitz type 1 and 2 conduction may also be seen depending on the rate of the atrial tachycardia and the conducting properties of the AV node. The appearance of "grouped beating" as seen in Mobitz type 1 conduction (Wenckebach) favors focal atrial tachycardia as the responsible mechanism for SVT.</p><p class="headingAnchor" id="H12"><span class="h3">QRS morphology</span><span class="headingEndMark"> — </span>The QRS morphology is usually the same as in sinus rhythm, although aberrant conduction may occur at higher ventricular rates.</p><p class="headingAnchor" id="H189482685"><span class="h2">Localization of AT focus</span><span class="headingEndMark"> — </span>Algorithms which attempt to predict the origin of the atrial tachycardia focus have been proposed [<a href="#rid6">6,10,28</a>]. </p><p>A P-wave algorithm was developed to predict the site of AT origin to guide mapping and ablation at the time of electrophysiology study. A study of 126 patients undergoing electrophysiology study for focal AT served as the basis for an algorithm that was able to predict the arrhythmogenic focus in 93 percent of ATs  (<a class="graphic graphic_algorithm graphicRef53718" href="/d/graphic/53718.html" rel="external">algorithm 1</a>) [<a href="#rid10">10</a>]. The algorithm begins with an evaluation of the P wave in lead V1 [<a href="#rid10">10</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>If the P wave in V1 is negative or biphasic with an initially positive/terminally negative deflection, the AT focus is likely in the right atrium  (<a class="graphic graphic_waveform graphicRef74611" href="/d/graphic/74611.html" rel="external">waveform 1</a> and <a class="graphic graphic_waveform graphicRef50523" href="/d/graphic/50523.html" rel="external">waveform 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the P wave in V1 is biphasic with an initial negative/terminally positive deflection, the AT focus is likely paraseptal and may require transseptal puncture or mapping of the noncoronary cusp.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the P wave in V1 is positive, the AT focus is likely in the left atrium  (<a class="graphic graphic_waveform graphicRef57390" href="/d/graphic/57390.html" rel="external">waveform 3</a>) with the exception of the crista terminalis.</p><p></p><p>With close inspection of the P wave in other leads, likely sites of origin could be predicted, including those in the coronary sinus, crista terminalis, left atrial appendage, right atrial appendage, interatrial septum, or pulmonary veins.</p><p>This algorithm was later simplified and updated with equivalent accuracy [<a href="#rid29">29</a>]. The revised algorithm included the following changes: focal AT arising from the coronary sinus os, right septum, perinodal, left septum, noncoronary cusp, and superior mitral annulus regions were grouped together as paraseptal AT. The term "paraseptal" was defined as anatomic sites in close proximity to either side of the interatrial septum with a similar-appearing P wave. Coronary sinus body was removed from the revised algorithm. The presence of an isoelectric versus negative P wave in lead I was used to discriminate between left pulmonary vein/left atrial appendage AT and right pulmonary vein AT.</p><p class="headingAnchor" id="H14"><span class="h2">Electrophysiologic study and catheter ablation</span><span class="headingEndMark"> — </span>The electrophysiologic evaluation of ATs is complex and the characteristics of the arrhythmia depend upon the mechanism [<a href="#rid3">3,4</a>]. The studies are best performed initially under light sedation as automatic ATs may be more difficult to induce under deeper sedation or general anesthesia. Other ATs are inducible by premature stimulation, and less sensitive to the effects of anesthesia. The findings on electrophysiologic study vary depending upon the mechanism of AT:</p><p class="bulletIndent1"><span class="glyph">●</span>Automatic ATs cannot be initiated, entrained, or terminated by electrophysiologic stimulation  (<a class="graphic graphic_waveform graphicRef90888" href="/d/graphic/90888.html" rel="external">waveform 4</a>). They may be initiated with <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> or adrenaline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Microreentrant ATs can be initiated, terminated, and entrained by programmed stimulation.</p><p></p><p>The ability to identify the focus responsible for AT has improved with the development of invasive three-dimensional mapping systems. Once a focus has been identified, treatment with catheter ablation can be performed during the same setting. The development of high density multi-electrode mapping catheters can assist in the localization of focal AT. (See <a class="local">'Chronic or maintenance therapy'</a> below.)</p><p class="headingAnchor" id="H2631740251"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Focal AT originating from the crista terminalis may be difficult to distinguish from inappropriate sinus node tachycardia, as the P wave will be similar. Focal AT more often occurs in bursts of atrial activity with rapid onset/offset compared with a more gradual acceleration and slowing seen with IAST. Additionally, IAST more often has a postural component with tachycardia on standing, an excessive heart rate response to exertion, and is responsive to <a class="drug drug_general" data-topicid="101166" href="/d/drug information/101166.html" rel="external">ivabradine</a> [<a href="#rid30">30</a>]. (See  <a class="medical medical_review" href="/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Inappropriate sinus tachycardia'</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>The management of focal AT is divided into acute treatment and chronic suppressive, or prophylactic, therapy. There are few data to guide treatment strategies. Our approach is consistent with that presented in the 2019 European Society of Cardiology guidelines for the management of supraventricular arrhythmias [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H16"><span class="h2">Acute treatment</span><span class="headingEndMark"> — </span>The acute management of a patient with an AT is guided by the ventricular rate, symptoms, and the hemodynamic stability of the patient. (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Assessing the patient for hemodynamic stability'</a> and  <a class="medical medical_review" href="/d/html/936.html" rel="external">"Overview of the acute management of tachyarrhythmias", section on 'Atrial tachycardia'</a>.)</p><p>There have been no randomized trials to assess the efficacy of the acute pharmacologic management of AT. For the acute management of patients with AT with a rapid ventricular response, we suggest the following approach, which is based upon small case series and retrospective studies, but is in general agreement with professional society guidelines [<a href="#rid6">6,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Efforts should be made to identify and treat any precipitating factors (see <a class="local">'Associated conditions'</a> above). In particular, patients who present with hypokalemia should have potassium repleted.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Efforts can be made to terminate focal AT by having the patient perform vagal maneuvers or by administering intravenous <a class="drug drug_general" data-topicid="9359" href="/d/drug information/9359.html" rel="external">adenosine</a>  (<a class="graphic graphic_algorithm graphicRef141417" href="/d/graphic/141417.html" rel="external">algorithm 2</a>) [<a href="#rid31">31</a>]. However, vagal maneuvers and adenosine are generally less effective for termination of AT than for atrioventricular (AV) nodal dependent supraventricular tachycardias (SVT). Intravenous adenosine is an important diagnostic tool in patients with SVT as generally AV nodal dependent tachycardias will terminate provided sufficient dosing and administration of adenosine. In most forms of AT, adenosine may unmask persisting rapid atrial activity in the presence of transient AV slowing. (See  <a class="medical medical_review" href="/d/html/1034.html" rel="external">"Vagal maneuvers"</a> and  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation", section on 'Intravenous adenosine'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Intravenous beta blockers (eg, <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> or <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">esmolol</a>) or nondihydropyridine calcium channel blockers (eg, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) may be given to the hemodynamically stable patient. These drugs should not be used in decompensated heart failure. They slow the ventricular response and may terminate the arrhythmia. In patients with a borderline blood pressure, cautious use of these medications (initially at low doses) may paradoxically improve blood pressure due to improved cardiac output at lower heart rates.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">Metoprolol</a> can be given as a 2.5 to 5 mg IV bolus over two to five minutes; if there is no response, an additional bolus may be administered every 10 minutes to a total dose of 15 mg.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">Diltiazem</a> can be given 20 mg IV bolus over two minutes; this may be repeated after 15 minutes if there is an inadequate response.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> can be given 5 to 10 mg IV bolus over two minutes; if no response, an additional 10 mg IV bolus may be administered 15 to 30 minutes following the initial dose.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are intolerant of, or are likely to be intolerant of, beta blockers and nondihydropyridine calcium channel blockers, we suggest intravenous <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, which can provide acute rate control, may terminate the arrhythmia, and results in less hypotension than beta blockers, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>. In appropriately selected patients, class IC (eg, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>) or class III (eg, <a class="drug drug_general" data-topicid="9941" href="/d/drug information/9941.html" rel="external">sotalol</a>) antiarrhythmic drugs can also be used. However, because of the unique risk profiles of each of these agents, decisions regarding the use of antiarrhythmic drugs, other than amiodarone, should be made with the assistance of a cardiologist experienced in arrhythmia management. In particular, class IC drugs are contraindicated in the setting of structural heart disease. In patients without structural heart disease, sotalol or flecainide is preferable to amiodarone as they are less toxic long-term therapies.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with hemodynamically unstable AT with a rapid ventricular response who do not respond to medical therapy and do not have a reversible precipitating cause, we suggest an attempt at electrical cardioversion.</p><p></p><p class="bulletIndent1">However, ATs may be particularly resistant to cardioversion for two reasons. First, many ATs are caused by enhanced automaticity, and electrical cardioversion is ineffective for such arrhythmias. Secondly, ATs are often precipitated by significant underlying illnesses that both limit the efficacy of cardioversion and increase the likelihood of early arrhythmia recurrence. (See <a class="local">'Electrophysiologic mechanisms'</a> above and <a class="local">'Associated conditions'</a> above.)</p><p></p><p class="bulletIndent1">Hemodynamically unstable patients with persistent AT despite treatment with rate-controlling medications and efforts at electrical cardioversion should have an attempt at chemical cardioversion using <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>.</p><p></p><p class="headingAnchor" id="H4348457"><span class="h2">Chronic or maintenance therapy</span><span class="headingEndMark"> — </span>Chronic therapy of repetitive focal AT is designed to prevent arrhythmia recurrence and to control the ventricular rate if the arrhythmia recurs. Patients with relatively rare and brief arrhythmias and few or no symptoms do not require maintenance therapy. In the absence of coexisting atrial fibrillation/flutter, atrial tachycardia carries a low risk of systemic embolization and chronic oral anticoagulation is not necessary.</p><p>The published literature addressing chronic suppressive treatment of AT includes only observational studies of small numbers of patients [<a href="#rid32">32</a>]. Some of these studies included patients with atrial fibrillation and atrial flutter, which have different mechanisms and may respond differently to therapy. With these limitations in mind, we suggest the following approach for chronic treatment of patients with frequent or symptomatic AT, which is in general agreement with professional society guidelines [<a href="#rid6">6,31</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Since focal AT may be short in duration and resolve spontaneously, we suggest initial therapy with oral beta blockers or nondihydropyridine calcium channel blockers (ie, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>). Patients who do not respond to one of these agents may have successful suppression with another.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with recurrent or refractory symptomatic AT despite therapy with beta blockers, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, or patients who would potentially require long-term pharmacologic therapy are candidates for catheter ablation. The threshold for considering catheter ablation is lower for younger patients, incessant tachycardia, and in patients with tachycardia-mediated cardiomyopathy. (See <a class="local">'Incessant AT resulting in cardiomyopathy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>More aggressive antiarrhythmic drugs may be considered for patients who fail beta blockers, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>, and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> who do not want or are not good candidates for ablation therapy. Class IC (eg, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/d/drug information/9821.html" rel="external">propafenone</a>) antiarrhythmic drugs can be used in appropriately selected patients in the absence of structural or ischemic heart disease. However, because of the unique risk profiles of each of these agents, decisions regarding the use of antiarrhythmic drugs should be made with the assistance of a cardiologist experienced in arrhythmia management. In patients with significant comorbidities and structural heart disease, <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is frequently the preferred agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with recurrent symptomatic AT in whom all other therapeutic options have been unsuccessful (including catheter ablation) may also be considered for pacemaker implantation and should preferably include biventricular or his bundle pacing followed by AV nodal ablation. This typically provides symptomatic relief although generally leaves the patient pacemaker dependent.</p><p></p><p class="headingAnchor" id="H2294907"><span class="h3">Catheter ablation</span><span class="headingEndMark"> — </span>With the advent of 3D mapping systems and high density multipolar mapping systems, radiofrequency ablation offers a potential cure in patients with recurrent atrial tachycardia [<a href="#rid33">33</a>]. In a large single-center series, mapping and ablation was performed in 303 of 345 (90 percent) patients for focal AT. Radiofrequency ablation (RFA) was not pursued in the remainder due to close proximity to the AV node, multiple changing morphologies or insufficient ectopy/tachycardia to allow the detailed mapping required to identify the responsible atrial focus. Success off medication was achieved in 272 of 303 (90 percent) patients [<a href="#rid2">2</a>].</p><p>Multiple ectopic atrial foci and the presence of structural cardiac disease are predictors of recurrence after an initially successful ablation [<a href="#rid21">21</a>].</p><p>Mapping and ablating atrial tachycardia is technically more challenging than other forms of paroxysmal SVT [<a href="#rid34">34</a>]. Atrial tachycardia can originate from any site in the right or left atrium, and even from the proximal pulmonary veins or superior vena cava. Identification of a tachycardia's origin as left versus right atrial may be difficult  (<a class="graphic graphic_figure graphicRef62431" href="/d/graphic/62431.html" rel="external">figure 2</a>) but can usually be successfully predicted using the surface ECG  (<a class="graphic graphic_algorithm graphicRef53718" href="/d/graphic/53718.html" rel="external">algorithm 1</a>). Localizing the origin of atrial tachycardia is discussed in detail elsewhere. (See <a class="local">'Localization of AT focus'</a> above and  <a class="medical medical_review" href="/d/html/980.html" rel="external">"Invasive diagnostic cardiac electrophysiology studies", section on 'Mapping and ablation'</a>.)</p><p class="headingAnchor" id="H102460167"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>Atrial tachycardia carries a low risk of systemic embolization in the absence of co-existing atrial fibrillation/flutter, and chronic oral anticoagulation is not necessary.</p><p class="headingAnchor" id="H9439996"><span class="h2">Treatment of incessant AT</span><span class="headingEndMark"> — </span>As described above, patients with incessant AT may present with a cardiomyopathy. Even patients with normal left ventricular systolic function on initial presentation are at risk of developing a cardiomyopathy following extended periods of tachycardia. This LV systolic dysfunction typically reverses weeks to months following the restoration of sinus rhythm. As such, aggressive efforts should be made to restore normal sinus rhythm in an attempt to prevent or reverse LV systolic dysfunction. (See <a class="local">'Incessant AT resulting in cardiomyopathy'</a> above and  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>While there have been occasional reports of the successful treatment of incessant AT using beta blockers and Class IC antiarrhythmic drugs (ie, <a class="drug drug_general" data-topicid="8449" href="/d/drug information/8449.html" rel="external">flecainide</a>), pharmacologic therapy is generally <strong>ineffective</strong> in incessant AT [<a href="#rid6">6,35-37</a>]. For this reason, if medical therapy with rate-controlling medications and antiarrhythmic drugs is unsuccessful, patients with AT and concomitant LV systolic dysfunction should undergo catheter ablation  (<a class="graphic graphic_waveform graphicRef50523" href="/d/graphic/50523.html" rel="external">waveform 2</a>) [<a href="#rid6">6</a>]. Only 10 to 15 percent of patients will have recurrence of AT following catheter ablation. (See <a class="local">'Catheter ablation'</a> above.)</p><p class="headingAnchor" id="H924999384"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H1509844"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – Atrial tachycardia (AT) is a regular atrial rhythm at a constant rate of &gt;100 beats per minute, usually paroxysmal and self-limited, which originates outside of the sinus node. Focal AT accounts for between 5 and 15 percent of paroxysmal supraventricular tachycardia in adults. (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sites of origin</strong> – The majority of ATs originate in the right atrium along the crista terminalis and tricuspid annulus. Left AT predominantly originates near the pulmonary veins. (See <a class="local">'Sites of origin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms</strong> – Most patients with focal AT report palpitations. Rarely, patients may present with syncope or exacerbation of an underlying cardiac condition (eg, angina). (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>ECG features</strong> – The P-wave morphology can appear normal or abnormal, depending upon the site of origin of the tachycardia. Usually, there is a subtle difference in P waves from sinus rhythm to AT, so comparison with an ECG with known sinus P waves is advised, whenever possible. (See <a class="local">'Electrocardiographic features'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute treatment</strong> – The acute treatment of patients with AT depends upon the presence of symptoms and the patient’s hemodynamic status:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For symptomatic patients</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hemodynamically unstable</strong> – Patients who are hemodynamically unstable are not candidates for medical therapy with intravenous beta blocker or nondihydropyridine calcium channel blocker because these treatments are likely to exacerbate hypotension. For such patients, we proceed with an attempt at electrical cardioversion, however this may be unsuccessful in patients with automatic AT. Hemodynamically unstable patients with persistent AT despite treatment with rate-controlling medications and efforts at electrical cardioversion should have an attempted chemical cardioversion using intravenous <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>. (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Hemodynamically stable</strong> – For a hemodynamically stable patient with symptomatic AT, we suggest acute treatment with an oral or intravenous beta blocker or nondihydropyridine calcium channel blocker (ie, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) rather than an antiarrhythmic drug (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Such treatment may slow the ventricular response and/or terminate the arrhythmia. Intravenous <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a> is an acceptable alternative that may be preferred in a patient with borderline hypotension with structural heart disease. (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For asymptomatic patients</strong> – For an asymptomatic hemodynamically stable patient with AT, we suggest initial observation rather than acute treatment with a beta blocker or nondihydropyridine calcium channel blocker (ie, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Acute treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic therapy</strong> – Chronic therapy of repetitive focal AT is designed to prevent arrhythmia recurrence and to control the ventricular rate if the arrhythmia recurs.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For rare or brief episodes</strong> – Patients with relatively rare or brief AT episodes with few or no symptoms can receive treatment as needed for acute episodes of AT but do not require chronic suppressive therapy. (See <a class="local">'Chronic or maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For frequent symptomatic episodes</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Initial therapy</strong> – For patients with frequent, symptomatic AT, we suggest chronic management with an oral beta blocker or nondihydropyridine calcium channel blocker (ie, <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> or <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>) as the initial treatment rather than an antiarrhythmic drug or catheter ablation (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Chronic or maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>For recurrent or refractory episodes</strong> – Patients with frequent, symptomatic AT who have failed initial medical therapy or require long-term medical therapy are candidates for catheter ablation. (See <a class="local">'Chronic or maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>For incessant AT</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>For few or no symptoms</strong> – For patients with incessant AT with preserved left ventricular function and few or no symptoms, an initial trial of rate-controlling medications or antiarrhythmic medications may be reasonable. The efficacy of this approach should be reassessed within two weeks and, if unsuccessful, the patient should be referred for catheter ablation. (See <a class="local">'Treatment of incessant AT'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>For cardiomyopathy related to incessant AT</strong> – For patients with cardiomyopathy felt to be related to incessant AT, we recommend aggressive attempts to restore a normal ventricular heart rate rather than rate control alone (<a class="grade" href="https://medilib.ir/uptodate/show/grade_2" rel="external">Grade 1B</a>). This can be accomplished in most patients by catheter ablation of the AT focus. In the unusual likelihood that catheter ablation is unsuccessful, pacemaker implantation, preferably including biventricular or his bundle pacing followed by atrioventricular nodal ablation, typically provides symptomatic relief. (See <a class="local">'Catheter ablation'</a> above and  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy", section on 'Treatment'</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Saoudi N, Cosío F, Waldo A, et al. A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 2001; 22:1162.</a></li><li><a class="nounderline abstract_t">Medi C, Kalman JM, Haqqani H, et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 2009; 53:1791.</a></li><li><a class="nounderline abstract_t">Chen SA, Chiang CE, Yang CJ, et al. Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation. Circulation 1994; 90:1262.</a></li><li><a class="nounderline abstract_t">Roberts-Thomson KC, Kistler PM, Kalman JM. Atrial tachycardia: mechanisms, diagnosis, and management. Curr Probl Cardiol 2005; 30:529.</a></li><li><a class="nounderline abstract_t">Roberts-Thomson KC, Kistler PM, Kalman JM. Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location. Pacing Clin Electrophysiol 2006; 29:643.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016; 133:e506.</a></li><li><a class="nounderline abstract_t">Higa S, Tai CT, Lin YJ, et al. Focal atrial tachycardia: new insight from noncontact mapping and catheter ablation. Circulation 2004; 109:84.</a></li><li><a class="nounderline abstract_t">De Groot NM, Schalij MJ. Fragmented, long-duration, low-amplitude electrograms characterize the origin of focal atrial tachycardia. J Cardiovasc Electrophysiol 2006; 17:1086.</a></li><li><a class="nounderline abstract_t">Kistler PM, Sanders P, Hussin A, et al. Focal atrial tachycardia arising from the mitral annulus: electrocardiographic and electrophysiologic characterization. J Am Coll Cardiol 2003; 41:2212.</a></li><li><a class="nounderline abstract_t">Kistler PM, Roberts-Thomson KC, Haqqani HM, et al. P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin. J Am Coll Cardiol 2006; 48:1010.</a></li><li><a class="nounderline abstract_t">Wong MC, Kalman JM, Ling LH, et al. Left septal atrial tachycardias: electrocardiographic and electrophysiologic characterization of a paraseptal focus. J Cardiovasc Electrophysiol 2013; 24:413.</a></li><li><a class="nounderline abstract_t">Ouyang F, Ma J, Ho SY, et al. Focal atrial tachycardia originating from the non-coronary aortic sinus: electrophysiological characteristics and catheter ablation. J Am Coll Cardiol 2006; 48:122.</a></li><li class="breakAll">Akhtar, M. Supraventricular tachycardias. Electrophysiologic mechanisms, diagnosis and pharmacologic therapy. In: Tachycardias: Mechanisms, Diagnosis, Treatment, Josephson, ME, Wellens, H (Eds), Lea &amp; Febiger, Philadelphia 1984. p.137.</li><li><a class="nounderline abstract_t">Levine HD, Smith C Jr. Repetitive paroxysmal tachycardia in adults. Cardiology 1970; 55:2.</a></li><li><a class="nounderline abstract_t">Sung RJ. Incessant supraventricular tachycardia. Pacing Clin Electrophysiol 1983; 6:1306.</a></li><li><a class="nounderline abstract_t">Gillette PC, Smith RT, Garson A Jr, et al. Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy. JAMA 1985; 253:391.</a></li><li><a class="nounderline abstract_t">Gillette PC, Wampler DG, Garson A Jr, et al. Treatment of atrial automatic tachycardia by ablation procedures. J Am Coll Cardiol 1985; 6:405.</a></li><li><a class="nounderline abstract_t">Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. Am J Cardiol 1986; 57:563.</a></li><li><a class="nounderline abstract_t">Bertil Olsson S, Blomström P, Sabel KG, William-Olsson G. Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture. Am J Cardiol 1984; 53:1465.</a></li><li><a class="nounderline abstract_t">Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.</a></li><li><a class="nounderline abstract_t">Chen SA, Tai CT, Chiang CE, et al. Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation. J Cardiovasc Electrophysiol 1998; 9:355.</a></li><li><a class="nounderline abstract_t">Koike K, Hesslein PS, Finlay CD, et al. Atrial automatic tachycardia in children. Am J Cardiol 1988; 61:1127.</a></li><li><a class="nounderline abstract_t">Kistler PM, Sanders P, Fynn SP, et al. Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation. Circulation 2003; 108:1968.</a></li><li><a class="nounderline abstract_t">O'Neill MD, Wright M, Knecht S, et al. Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint. Eur Heart J 2009; 30:1105.</a></li><li><a class="nounderline abstract_t">Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med 2015; 372:1812.</a></li><li><a class="nounderline abstract_t">Tisdale JE, Chung MK, Campbell KB, et al. Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association. Circulation 2020; 142:e214.</a></li><li><a class="nounderline abstract_t">Zipes DP, Gaum WE, Genetos BC, et al. Atrial tachycardia without P waves masquerading as an A-V junctional tachycardia. Circulation 1977; 55:253.</a></li><li><a class="nounderline abstract_t">Qian ZY, Hou XF, Xu DJ, et al. An algorithm to predict the site of origin of focal atrial tachycardia. Pacing Clin Electrophysiol 2011; 34:414.</a></li><li><a class="nounderline abstract_t">Kistler PM, Chieng D, Tonchev IR, et al. P-Wave Morphology in Focal Atrial Tachycardia: An Updated Algorithm to Predict Site of Origin. JACC Clin Electrophysiol 2021; 7:1547.</a></li><li><a class="nounderline abstract_t">Cappato R, Castelvecchio S, Ricci C, et al. Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation. J Am Coll Cardiol 2012; 60:1323.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Kang KT, Etheridge SP, Kantoch MJ, et al. Current management of focal atrial tachycardia in children: a multicenter experience. Circ Arrhythm Electrophysiol 2014; 7:664.</a></li><li><a class="nounderline abstract_t">Chieng D, Lahiri A, Sugumar H, et al. Multipolar mapping with the high-density grid catheter compared with conventional point-by-point mapping to guide catheter ablation for focal arrhythmias. J Cardiovasc Electrophysiol 2020; 31:2288.</a></li><li class="breakAll">Lesh MD. Radiofrequency catheter ablation of atrial tachycardia and flutter. In: Cardiac Electrophysiology: From Cell to Bedside, 2nd ed, Zipes DP, Jalife J (Eds), WB Saunders, Philadelphia 1995. p.1461.</li><li><a class="nounderline abstract_t">Iwai S, Markowitz SM, Stein KM, et al. Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping. Circulation 2002; 106:2793.</a></li><li><a class="nounderline abstract_t">Berns E, Rinkenberger RL, Jeang MK, et al. Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987; 59:1337.</a></li><li><a class="nounderline abstract_t">Brugada P, Abdollah H, Wellens HJ. Suppression of incessant supraventricular tachycardia by intravenous and oral encainide. J Am Coll Cardiol 1984; 4:1255.</a></li></ol></div><div id="topicVersionRevision">Topic 900 Version 36.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11440490" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : A classification of atrial flutter and regular atrial tachycardia according to electrophysiological mechanisms and anatomical bases; a Statement from a Joint Expert Group from The Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422986" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8087935" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Sustained atrial tachycardia in adult patients. Electrophysiological characteristics, pharmacological response, possible mechanisms, and effects of radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16182016" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Atrial tachycardia: mechanisms, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16784432" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Focal atrial tachycardia I: clinical features, diagnosis, mechanisms, and anatomic location.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399663" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14691042" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Focal atrial tachycardia: new insight from noncontact mapping and catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16989650" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Fragmented, long-duration, low-amplitude electrograms characterize the origin of focal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12821250" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Focal atrial tachycardia arising from the mitral annulus: electrocardiographic and electrophysiologic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16949495" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : P-wave morphology in focal atrial tachycardia: development of an algorithm to predict the anatomic site of origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252694" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Left septal atrial tachycardias: electrocardiographic and electrophysiologic characterization of a paraseptal focus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814658" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Focal atrial tachycardia originating from the non-coronary aortic sinus: electrophysiological characteristics and catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16814658" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Focal atrial tachycardia originating from the non-coronary aortic sinus: electrophysiological characteristics and catheter ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4103601" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Repetitive paroxysmal tachycardia in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6196741" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Incessant supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3965793" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Chronic supraventricular tachycardia. A curable cause of congestive cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4019927" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Treatment of atrial automatic tachycardia by ablation procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3953440" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6720596" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incessant ectopic atrial tachycardia: successful surgical treatment with regression of dilated cardiomyopathy picture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1554546" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incessant atrial tachycardia accelerated by pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9581952" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Focal atrial tachycardia: reanalysis of the clinical and electrophysiologic characteristics and prediction of successful radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2896454" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Atrial automatic tachycardia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557361" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Electrophysiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radiofrequency ablation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19270341" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Long-term follow-up of persistent atrial fibrillation ablation using termination as a procedural endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25946280" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Approaches to catheter ablation for persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32929996" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Drug-Induced Arrhythmias: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/64319" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Atrial tachycardia without P waves masquerading as an A-V junctional tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091746" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : An algorithm to predict the site of origin of focal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34217661" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : P-Wave Morphology in Focal Atrial Tachycardia: An Updated Algorithm to Predict Site of Origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22981555" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical efficacy of ivabradine in patients with inappropriate sinus tachycardia: a prospective, randomized, placebo-controlled, double-blind, crossover evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25015944" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Current management of focal atrial tachycardia in children: a multicenter experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32583514" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Multipolar mapping with the high-density grid catheter compared with conventional point-by-point mapping to guide catheter ablation for focal arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32583514" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Multipolar mapping with the high-density grid catheter compared with conventional point-by-point mapping to guide catheter ablation for focal arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451005" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Response to adenosine differentiates focal from macroreentrant atrial tachycardia: validation using three-dimensional electroanatomic mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3109229" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6438205" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
